Cara Shares Up On Positive Phase III Data For Itchiness Drug
Zacks Investment Research | May 30, 2019 07:48AM ET
Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) increased about 20% after the company announced positive top-line data from the KALM-1 pivotal phase III study of Korsuva (CR845/difelikefalin) injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus (CKD-aP). Cara’s shares have rallied 38.8% year to date compared with the industry ’s growth of 0.1%.
Itchiness is a common issue among patients on dialysis. The study showed that dialysis patients experiencing itchiness, who were given Korsuva injection, showed statistically significant improvement compared with those on placebo.
The phase III study KALM-1 is a multicenter, randomized, double-blind, placebo-controlled 12-week treatment trial (with a 52-week open label extension phase) that is designed to evaluate the safety and efficacy of 0.5 mcg/kg Korsuva injection in 350 hemodialysis patients with moderate-to-severe pruritus. The primary efficacy endpoint is the proportion of patients on 0.5 mcg/kg of Korsuva Injection achieving at least a three-point improvement from baseline in the weekly mean of the daily 24-hour worst itching intensity Numeric Rating Scale (NRS) score at week 12. Korsuva showed a three-point or greater improvement in itchiness after 12 weeks in 51% of patients, while only 28% showed improvement on placebo, per the company. Further, 39% percent of patients on the drug were able to show a four-point or greater improvement in itchiness compared with 18% of patients on placebo.
Korsuva injection resulted in statistically significant separation from placebo after only one week of treatment and a sustained significant benefit through 12 weeks.
Cara is focused on developing new chemical entities to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Korsuva is a first in class KOR agonist that targets the body's peripheral nervous system and certain immune cells. The successful development and commercialization of the candidate will significantly boost growth for the company. The FDA has conditionally accepted Korsuva as the trade name for difelikefalin injection.
The company had earlier inked a licensing deal with Vifor Fresenius Medical Care Renal Pharma Ltd., a joint company formed by Vifor Pharma Group and Fresenius Medical Care (NYSE:FMS) . Per the deal, Cara licensed worldwide rights except in the United States, Japan and South Korea to commercialize Korsuva injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP). Per the agreement, Cara will commercialize Korsuva injection in the United States & co-promote with VFMCRP in United States.
While there is huge potential for therapies to treat and manage postoperative acute pain, moderate-to-severe chronic pain and neuropathic pain, the competition is stiff from the likes of existing players like Mallinckrodt (NYSE:MNK) and Pacira Pharmaceuticals (NASDAQ:PCRX) , among others.
Get The News You Want
Cara Therapeutics, Inc. Price
Cara Therapeutics, Inc. Quote
Zacks Rank
Cara currently carries a Zacks Rank #3 (Hold). You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.